RecruitingPhase 4NCT06260878

Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis


Sponsor

University of Calgary

Enrollment

505 participants

Start Date

Nov 22, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Intravenous Ringer's lactate for people with post-ercp acute pancreatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERIntravenous Ringer's lactate

Intravenous Ringer's lactate


Locations(1)

Peter Lougheed Centre

Calgary, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06260878


Related Trials